Literature DB >> 12668212

Discovery and in vivo evaluation of new melanocortin-4 receptor-selective peptides.

Wouter A J Nijenhuis1, John A W Kruijtzer, Nienke Wanders, Dorien H Vrinten, Keith M Garner, Wim M M Schaaper, Rob H Meloen, Willem Hendrik Gispen, Rob M Liskamp, Roger A H Adan.   

Abstract

The melanocortin-4 receptor (MC4R) is involved in several physiological processes, including body weight regulation and grooming behaviour in rats. It has also been suggested that the MC4R mediates the effects of melanocortin ligands on neuropathic pain. Selective compounds are needed to study the exact role of the MC4R in these different processes. We describe here the development and evaluation of new melanocortin compounds that are selective for the MC4R as compared with the other centrally expressed receptors, MC3R and MC5R. First, a library of 18 peptides, in which a melanocortin-based sequence was systematically point-mutated, was screened for binding to and activity on the MC3R, MC4R and MC5R. Compound Ac-Nle-Gly-Lys-D-Phe-Arg-Trp-Gly-NH(2) (JK1) appeared to be the most selective MC4R compound, based on affinity. This compound is 90- and 110-fold selective for the MC4R as compared to the MC3R and MC5R, respectively. Subsequent modification of JK1 yielded compound Ac-Nle-Gly-Lys-D-Nal(2)-Arg-Trp-Gly-NH(2) (JK7)(,) a selective MC4R antagonist with 34-fold MC4R/MC3R and 109-fold MC4R/MC5R selectivity. The compounds were active in vivo as determined in a grooming assay and a model for neuropathic pain in rats. Intravenous (i.v.) injections suggested that they were able to pass the blood-brain barrier.The compounds identified here will be useful in further research on the physiological roles of the MC4R.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668212     DOI: 10.1016/s0196-9781(03)00032-9

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  6 in total

1.  Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists.

Authors:  Irina D Pogozheva; Biao-Xin Chai; Andrei L Lomize; Tung M Fong; David H Weinberg; Ravi P Nargund; Michael W Mulholland; Ira Gantz; Henry I Mosberg
Journal:  Biochemistry       Date:  2005-08-30       Impact factor: 3.162

2.  Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities.

Authors:  Alexander V Mayorov; Minying Cai; Kevin B Chandler; Ravil R Petrov; April R Van Scoy; Zerui Yu; Dustin K Tanaka; Dev Trivedi; Victor J Hruby
Journal:  J Med Chem       Date:  2006-03-23       Impact factor: 7.446

3.  Cyclic lactam hybrid α-MSH/Agouti-related protein (AGRP) analogues with nanomolar range binding affinities at the human melanocortin receptors.

Authors:  Alexander V Mayorov; Minying Cai; Erin S Palmer; Dustin K Tanaka; James P Cain; Matthew M Dedek; Bahar Tan; Dev Trivedi; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2011-03-13       Impact factor: 2.823

4.  Novel selective human melanocortin-3 receptor ligands: use of the 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (Aba) scaffold.

Authors:  Steven Ballet; Alexander V Mayorov; Minying Cai; Dagmara Tymecka; Kevin B Chandler; Erin S Palmer; Karolien Van Rompaey; Aleksandra Misicka; Dirk Tourwé; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2007-02-09       Impact factor: 2.823

5.  GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report.

Authors:  Eva W Iepsen; Christian T Have; Simon Veedfald; Sten Madsbad; Jens J Holst; Niels Grarup; Oluf Pedersen; Ivan Brandslund; Jens-Christian Holm; Torben Hansen; Signe S Torekov
Journal:  Cell Rep Med       Date:  2020-04-21

6.  Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 receptor.

Authors:  Alexander V Mayorov; Minying Cai; Erin S Palmer; Matthew M Dedek; James P Cain; April R Van Scoy; Bahar Tan; Josef Vagner; Dev Trivedi; Victor J Hruby
Journal:  J Med Chem       Date:  2007-12-19       Impact factor: 7.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.